• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
【24h】

Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

机译：Dupilumab通过鼻息蛋白患病减少慢性鼻窦炎的局部2型促炎生物标志物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2-mediated inflammatory disease associated with significant clinical, social, and economic burdens and high unmet therapeutic need. Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4R alpha) subunit, demonstrated efficacy and acceptable safety in CRSwNP and other type 2 diseases (eg, atopic dermatitis and asthma). We now report the local effects of dupilumab on type 2 inflammatory biomarkers in nasal secretions and nasal polyp tissues of patients with CRSwNP in a randomized, placebo-controlled, phase 2 trial (NCT01920893). Methods Cytokines, chemokines, and total immunoglobulin E (IgE) levels were measured using immunoassay techniques in nasal secretions and nasal polyp tissue homogenates of CRSwNP patients receiving dupilumab 300 mg or placebo weekly for 16 weeks. Results With dupilumab, type 2 biomarker concentrations decreased in nasal secretions (least squares mean area under the curve from 0 to 16 weeks for the change from baseline) vs placebo for eotaxin-3 (-30.06 vs -0.86 pg/mL; P = 0.0008) and total IgE (-7.90 vs -1.86 IU/mL; P = 0.022). Dupilumab treatment also decreased type 2 biomarker levels in nasal polyp tissues at Week 16 vs baseline for eosinophilic cationic protein (P = 0.008), eotaxin-2 (P = 0.008), eotaxin-3 (P = 0.031), pulmonary and activation-regulated chemokine (P = 0.016), IgE (P = 0.023), and IL-13 (P = 0.031). Conclusions Dupilumab treatment reduced multiple biomarkers of type 2 inflammation in nasal secretions and polyp tissues of patients with CRSwNP, demonstrating that antagonism of IL-4R alpha signaling suppresses IL-4-/IL-13-dependent processes, such as mucosal IgE formation, as well as the expression of chemokines attracting inflammatory cells to the nasal mucosa.
机译：背景技术慢性鼻炎患有鼻息肉（CRSWNP）是一种与重要的临床，社会和经济负担以及高未满足的治疗需求相关的2型介导的炎症疾病。杜帕里曼，靶向白细胞介素-4受体α（IL-4Rα）亚基的全人单克隆抗体，在CRSWNP和其他2型疾病（例如，特应性皮炎和哮喘）中表现出疗效和可接受的安全性。我们现在举报杜帕里米亚对随机，安慰剂的相2试验（NCT01920893）中CRSWNP患者鼻腔分泌物和鼻息糖组织的局部疗效。方法使用免疫测定技术在鼻腔分泌物中测量细胞因子，趋化因子和总免疫球蛋白E（IgE）水平，CRSWNP患者的CRSMPP患者每周接受杜帕里卢米夫或安慰剂16周。杜帕里曼的结果，2型生物标志物浓度在鼻分泌物（最小二乘范围为0至16周的曲线下的平均面积，用于从基线的变化）对Eotaxin-3的安慰剂（-30.06 Vs -0.86 pg / ml; p = 0.0008 ）和总IgE（-7.90 Vs -1.86 Iu / ml; p = 0.022）。杜帕米采购在第16周对嗜酸性阳离子蛋白的第16次VS基线（P = 0.008），Eotaxin-3（P = 0.031），肺和活化调节的第26条VS基线（P = 0.008），肺炎林-3（P = 0.031），肺和活化调节患者患有鼻息肉组织中的2种生物标志物水平趋化因子（P = 0.016），IgE（P = 0.023）和IL-13（P = 0.031）。结论Dupilumab治疗减少了CRSWNP患者鼻分泌物和息肉组织中2型炎症的多种生物标志物，证明了IL-4Rα信号传导的拮抗作用抑制了IL-4- / IL-13依赖性过程，例如粘膜IgE形成，如以及吸引炎症细胞到鼻粘膜的趋化因子的表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号